Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Other Operating Expenses (2018 - 2019)

Serina Therapeutics' Other Operating Expenses history spans 4 years, with the latest figure at -$3.0 million for Q4 2023.

  • For Q4 2023, Other Operating Expenses changed N/A year-over-year to -$3.0 million; the TTM value through Sep 2024 reached -$3.0 million, down 18.54%, while the annual FY2023 figure was $73000.0, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2023 was -$3.0 million at Serina Therapeutics, down from -$1.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $6.9 million in Q4 2019 and bottomed at -$6.9 million in Q1 2019.
  • The 3-year median for Other Operating Expenses is -$893000.0 (2020), against an average of -$831000.0.
  • The largest annual shift saw Other Operating Expenses soared 198.74% in 2019 before it plummeted 107.67% in 2020.
  • A 3-year view of Other Operating Expenses shows it stood at $6.9 million in 2019, then tumbled by 107.67% to -$529000.0 in 2020, then tumbled by 469.19% to -$3.0 million in 2023.
  • Per Business Quant, the three most recent readings for SER's Other Operating Expenses are -$3.0 million (Q4 2023), -$1.3 million (Q3 2023), and -$1.3 million (Q2 2023).